Project Grant K08CA312653
Award Date 9/3/26
Completion Date 8/31/31
Dollars Obligated $294K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $676,849 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to enhance MIRDSOFT.ORG, an open-source radiation dosimetry platform operated by the MIRD Committee of the Society of Nuclear Medicine and Molecular Imaging. The award funds development of computational human phantoms and dosimetry software to support personalized dose estimation in nuclear medicine and radiology. Deliverables...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $140,400 on July 17, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop multimodal, interpretable artificial intelligence models that integrate digital pathology images and tumor genomic data to improve precision cancer diagnosis and treatment selection. The award funds a two-phase K99/R00 career development grant. During the K99 phase, the recipient will study multimodal self-supervised...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The National Cancer Institute awarded Sloan-Kettering Institute For Cancer Research $263,073 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support research identifying genetic factors mediating alternative lengthening of telomeres (ALT) in cancer. The research targets ALT, a recombination-based telomere maintenance mechanism present in 10–15 percent of cancers, particularly sarcomas and gliomas. The investigator will conduct three aims: examining how chromatin...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $246,362 on June 12, 2026, under the Cancer Research Manpower program (CFDA 93.398) to investigate the mechanisms by which homologous recombination deficiency, particularly BRCA mutations, drives endocrine therapy resistance in estrogen receptor-positive breast cancer. The project will comprehensively characterize changes in BRCA2-associated ER+ breast cancers in response to endocrine therapy using patient...
- The National Cancer Institute, National Institutes of Health, awarded Sloan-Kettering Institute For Cancer Research $715,002 on April 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop HER2 positron emission tomography imaging methods for assessing HER2 heterogeneity and predicting response to HER2-targeted therapies in biliary tract cancer. The project addresses treatment resistance in metastatic biliary tract cancer by using molecular imaging to...
- The National Institutes of Health National Cancer Institute awarded Albert Einstein College of Medicine $431,970 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to refine and validate an MRI-based imaging technique for detecting tumor microenvironment of metastasis (TMEM) doorways in breast cancer. The award funds development of TMEM doorway activity-MRI (TDAM), a dynamic contrast-enhanced MRI method designed to measure vascular opening events...
- The National Cancer Institute awarded the University of California, Santa Cruz $128,940 under the Cancer Research Manpower program (CFDA 93.398) on January 12, 2026, to support research determining the effects of pregnancy and aging on the mammary gland and breast cancer risk reduction. The funded research investigates how early full-term pregnancy reduces breast cancer risk by altering the molecular and cellular processes in mammary epithelial cells (MECs). The project uses single-cell RNA...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded $644,423 to Sloan-Kettering Institute for Cancer Research on June 18, 2026, under the Cancer Treatment Research program (CFDA 93.395). The recipient will develop short-wave infrared (SWIR) Cerenkov luminescence imaging (SWIR-CLI) to visualize the distribution of therapeutic radiotracers and improve monitoring of targeted radiotherapy. Current Cerenkov luminescence imaging requires light-tight...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...